ECSP12012160A - Compuesto heterociclico - Google Patents
Compuesto heterociclicoInfo
- Publication number
- ECSP12012160A ECSP12012160A ECSP12012160A ECSP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A EC SP12012160 A ECSP12012160 A EC SP12012160A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- heterociclical
- salt
- useful
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporciona un compuesto útil como un agente profiláctico o terapéutico para cáncer. Se describe específicamente un compuesto representado por la fórmula (I) (en donde cada símbolo es como se define en la descripción) o una sal del mismo, o un promedicamento del compuesto o la sal del mismo, el cual es útil para la prevención o tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010031899 | 2010-02-17 | ||
JP2010131950 | 2010-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12012160A true ECSP12012160A (es) | 2013-03-28 |
Family
ID=44482985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12012160 ECSP12012160A (es) | 2010-02-17 | 2012-09-17 | Compuesto heterociclico |
Country Status (35)
Country | Link |
---|---|
US (6) | US8722660B2 (es) |
EP (2) | EP3533797B1 (es) |
JP (1) | JP5689454B2 (es) |
KR (1) | KR101735868B1 (es) |
CN (1) | CN102844320B (es) |
AU (1) | AU2011216404B2 (es) |
BR (1) | BR112012020311B1 (es) |
CA (1) | CA2790284C (es) |
CL (1) | CL2012002250A1 (es) |
CO (1) | CO6592104A2 (es) |
CR (1) | CR20120448A (es) |
CY (1) | CY1121792T1 (es) |
DK (1) | DK2540728T3 (es) |
DO (1) | DOP2012000224A (es) |
EA (1) | EA020724B1 (es) |
EC (1) | ECSP12012160A (es) |
ES (1) | ES2733221T3 (es) |
GE (1) | GEP20146202B (es) |
HR (1) | HRP20190947T1 (es) |
HU (1) | HUE043514T2 (es) |
IL (1) | IL221442A0 (es) |
LT (1) | LT2540728T (es) |
MA (1) | MA34064B1 (es) |
ME (1) | ME03410B (es) |
MX (1) | MX353500B (es) |
MY (1) | MY164776A (es) |
NZ (1) | NZ602089A (es) |
PE (1) | PE20130184A1 (es) |
PL (1) | PL2540728T3 (es) |
PT (1) | PT2540728T (es) |
RS (1) | RS58796B1 (es) |
SG (1) | SG183304A1 (es) |
SI (1) | SI2540728T1 (es) |
TN (1) | TN2012000401A1 (es) |
WO (1) | WO2011102399A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ607087A (en) * | 2010-08-11 | 2015-05-29 | Millennium Pharm Inc | Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders |
EP3100742B1 (en) | 2014-01-31 | 2020-05-20 | Carna Biosciences Inc. | Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor |
TW201620879A (zh) | 2014-04-28 | 2016-06-16 | 杜邦股份有限公司 | 除草性經取代之3-苯基-4-氟基苯甲醯基吡唑 |
US10174032B2 (en) * | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
CN108027849B (zh) | 2015-12-07 | 2020-03-20 | 齐默尔根公司 | 利用htp基因组工程平台对微生物菌株的改良 |
AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
CA3016708A1 (en) * | 2016-03-28 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate |
EA035560B1 (ru) * | 2016-07-28 | 2020-07-07 | Такеда Фармасьютикал Компани Лимитед | Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она |
EP3538523B1 (en) | 2016-11-08 | 2021-05-19 | Cancer Research Technology Limited | Pyrimidinone derivatives as cdc7 inhibitors |
EP3589747B1 (en) | 2017-03-01 | 2021-05-19 | Takeda Pharmaceutical Company Limited | Method of predicting effects of cdc7 inhibitor |
WO2018217439A1 (en) * | 2017-05-21 | 2018-11-29 | Zhang Hai Jun | Substituted [5,6]cyclic-4(3h)-pyrimidinones as anticancer agents |
EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
WO2019194319A1 (en) * | 2018-04-02 | 2019-10-10 | Takeda Pharmaceutical Company Limited | Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one |
TW202016316A (zh) | 2018-06-19 | 2020-05-01 | 日商武田藥品工業股份有限公司 | 癌症治療方法 |
US20210308061A1 (en) | 2018-07-19 | 2021-10-07 | Taked Pharmaceutical Company Limited | Pharmaceutical compositions with a cdc7 inhibitor |
KR20220027883A (ko) * | 2019-05-30 | 2022-03-08 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Cdc7 억제제로서의 테트라사이클릭 화합물 |
US20220323443A1 (en) | 2019-07-19 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Combination therapy for cancer treatment |
CN114127077B (zh) * | 2019-08-20 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 用作Cdc7抑制剂的四并环类化合物 |
EP4069369A4 (en) * | 2019-12-06 | 2024-02-14 | Schroedinger Inc | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
CN116490507A (zh) * | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
EP4253388A1 (en) * | 2020-11-30 | 2023-10-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt form used as cdc7 inhibitor and crystal form thereof |
CN112661770B (zh) * | 2020-12-24 | 2022-11-08 | 南京正济医药研究有限公司 | 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法 |
WO2022167999A1 (en) | 2021-02-08 | 2022-08-11 | Takeda Pharmaceutical Company Limited | Combination therapy for cancer treatment |
TW202300150A (zh) * | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196207A (en) * | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
JPWO2002026745A1 (ja) | 2000-09-29 | 2004-02-05 | 日本曹達株式会社 | チエノピリミジン化合物とその塩並びに製造方法 |
US6503914B1 (en) | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
MXPA05001389A (es) | 2002-08-06 | 2005-04-28 | Astrazeneca Ab | Piridinas y pirimidinas condensadas con actividad tie2 (tek). |
EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
SI1641803T1 (sl) * | 2003-06-11 | 2009-08-31 | Xention Ltd | Tienopirimidinski derivati kot inhibitorji kalijevih kanalov |
US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US7279575B2 (en) | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
BRPI0413438A (pt) * | 2003-08-08 | 2006-10-17 | Pharmacia Italia Spa | derivados de pirimidilpirrol ativos como inibidores de cinase |
RU2006138036A (ru) | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
EP2495324B1 (en) | 2004-04-09 | 2015-03-04 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
CA2595127A1 (en) | 2005-01-19 | 2006-07-27 | Paul J. Coleman | Mitotic kinesin inhibitors |
WO2007011284A1 (en) | 2005-07-15 | 2007-01-25 | Astrazeneca Ab | Therapeutic agents |
WO2007026664A1 (ja) | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
FI20055498A0 (fi) | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
US20090030196A1 (en) * | 2006-12-29 | 2009-01-29 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
US20090118276A1 (en) | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
EP2276747A1 (en) | 2008-03-11 | 2011-01-26 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
CN102132160A (zh) | 2008-06-26 | 2011-07-20 | 达纳-法伯癌症研究院有限公司 | 与转移有关的信号和决定子以及它们的使用方法及用途 |
US8691828B2 (en) | 2009-03-05 | 2014-04-08 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as CDC7 kinase inhibitors |
WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
EP2475366A1 (en) | 2009-09-11 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
AR079343A1 (es) | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
-
2011
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja active Application Filing
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active IP Right Grant
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
-
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
-
2014
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
-
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
-
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
-
2019
- 2019-05-23 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12012160A (es) | Compuesto heterociclico | |
CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
CL2019000844A1 (es) | Compuesto de piridina. | |
ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
EA201690020A1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
DOP2013000118A (es) | Compuesto bicíclico | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
PH12015501058A1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
TWD161529S (zh) | 治療燈 | |
ECSP10010526A (es) | Compuesto heterociclico | |
MX361499B (es) | Baricitinib deuterado. | |
DOP2014000243A (es) | Compuesto heterocíclico nitrogenado | |
DOP2015000140A (es) | Compuesto heterocíclico | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
EA201591024A1 (ru) | Димерные соединения | |
GT201500071A (es) | Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3 | |
PH12015500399A1 (en) | Azaindolines | |
EP4268891A3 (en) | Compound for use in methods for treatment of polycystic kidney disease | |
EA201491581A1 (ru) | Везикулярные композиции | |
UA117809C2 (uk) | Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку | |
EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |